Kaarina Kowalec

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. 2024;11(6):1393-1404
Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis
Kowalec K; Harder A; Dolovich C; Fitzgerald KC; Salter A; Lu Y; Bernstein CN; Bolton JM; Cutter G; Fisk JD; Gelernter J; Graff LA; Haegg S; Hitchon CA; Levey DF; Lublin FD; Mckay KA; Patten S; Patki A; Stein MB; Tiwari HK; Wolinsky JS; Marrie RA
Article: NEUROLOGY. 2024;102(5):e209135
Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations
Salter A; Lancia S; Kowalec K; Fitzgerald KC; Marrie RA
Article: PHARMACOGENOMICS. 2024;25(4):175-186
Knowledge and perceptions of pharmacogenomics among pharmacists in Manitoba, Canada
Al Maruf A; Shields M; Fryza A; Wondrasek A; Leong C; Kowalec K; Bousman C
Article: HEALTH SCIENCE REPORTS. 2024;7(1):e1844
Knowledge, perceptions, and attitudes toward pharmacogenomics among pharmacists and pharmacy students: A systematic review
Wondrasek A; Fryza A; Aziz MA; Leong C; Kowalec K; Al Maruf A
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2023;180(10):714-722
Genetic Contribution to the Heterogeneity of Major Depressive Disorder: Evidence From a Sibling-Based Design Using Swedish National Registers
Thuy-Dung N; Kowalec K; Pasman J; Larsson H; Lichtenstein P; Dalman C; Sullivan PF; Kuja-Halkola R; Lu Y
Article: TRANSLATIONAL PSYCHIATRY. 2023;13(1):301
Polygenic risk scores of lithium response and treatment resistance in major depressive disorder
Xiong Y; Karlsson R; Song J; Kowalec K; Rueck C; Sigstroem R; Jonsson L; Clements CC; Andersson E; Boberg J; Lewis CM; Sullivan PF; Landen M; Lu Y
Article: JOURNAL OF PSYCHOSOMATIC RESEARCH. 2023;172:111415
Assessment of differential item functioning of the PHQ-9, HADS-D and PROMIS-depression scales in persons with and without multiple sclerosis
Marrie RA; Lix LM; Bolton JM; Fisk JD; Fitzgerald KC; Graff LA; Hitchon CA; Kowalec K; Marriott JJ; Patten SB; Salter A; Bernstein CN
Article: NEUROLOGY. 2023;101(5):e522-e532
Polygenicity of Comorbid Depression in Multiple Sclerosis
Kowalec K; Fitzgerald KC; Salter A; Dolovich C; Harder A; Bernstein CN; Bolton J; Cutter GR; Graff LA; Hagg S; Hitchon CA; Lu Y; Lublin F; McKay KA; Patten SB; Patki A; Tiwari HK; Wolinsky JS; Marrie RA
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2023;43(4):313-319
Adherence to Psychotropic Medication Before and During COVID-19 A Population-Wide Retrospective Observational Study
Froese B; Aquino G; Valencia E; Tan Q; Yogendran M; Katz C; Bolton JM; Falk J; Kowalec K; Chateau D; Delaney JC; Logsetty S; Spiwak R; Enns MW; Sareen J; Alessi-Severini S; Olafson K; Eltonsy S; Leong C
Journal article: BMJ OPEN. 2023;13(6):e073782
Well-being and flourishing mental health in adults with inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis in Manitoba, Canada: a cross-sectional study.
Almweisheer S; Bernstein CN; Graff LA; Patten SB; Bolton J; Fisk JD; Hitchon CA; Marriott JJ; Marrie RA; CIHR Team in Defining the Burden and Managing the
Article: THE LANCET REGIONAL HEALTH. EUROPE. 2023;29:100621
Epidemiological overview of major depressive disorder in Scandinavia using nationwide registers
Pasman JA; Meijsen J; Haram M; Kowalec K; Harder A; Xiong Y; Nguyen T-D; Jangmo A; Shorter JR; Bergstedt J; Das U; Zetterberg R; Tate A; Lichtenstein P; Larsson H; Odsbu I; Werge T; Reichborn-Kjennerud T; Andreassen OA; Sullivan PF; Buil A; Tesli M; Lua Y
Article: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2023;45(1):233-239
Sex differences among users of NSAIDs and opioids during COVID-19 Pandemic
Offiah R; Aboulatta L; Peymani P; Aloud B; Kowalec K; Leong C; Delaney J; Falk J; Alessi-Severini S; Eltonsy S
Article: BMJ PAEDIATRICS OPEN. 2023;7(1):e001686
Preterm birth and stillbirth rates associated with socioeconomic disparities during COVID-19 pandemic: a population-based cross-sectional study
Aboulatta L; Kowalec K; Leong C; Delaney JA; Falk J; Alessi-Severini S; Chateau D; Tan Q; Kearns K; Raimondi C; Vaccaro C; Lavu A; Haidar L; Peymani P; Eltonsy S
Article: FRONTIERS IN PSYCHIATRY. 2023;14:1260420
Sex differences evident in elevated anxiety symptoms in multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis
Joyees J; Marrie RA; Bernstein CN; Bolton JM; Fisk JD; Graff LA; Hitchon C; Patten SB; Kowalec K
Article: NEUROLOGY: NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2023;10(1):e200062
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis
Vasileiou ES; Hu C; Bernstein CN; Lublin F; Wolinsky JS; Cutter GR; Sotirchos ES; Kowalec K; Salter A; Saidha S; Mowry EM; Calabresi PA; Marrie RA; Fitzgerald KC
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2022;179(11):844-852
Association Between Polygenic Risk Scores and Outcome of ECT
Sigstrom R; Kowalec K; Jonsson L; Clements CC; Karlsson R; Nordenskjold A; Palsson E; Sullivan PF; Landen M
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2022;63:e31-e32
TRYGGVE2: SECURE & PRECISE GENETIC ANALYSES IN THE NORDIC COUNTRIES AND BEYOND
Lu Y; Kowalec K; Werge T; Andreassen O; Sullivan P
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2022;63:e270
INVESTIGATING GENETIC OVERLAP BETWEEN ANTIDEPRESSANTS AND LITHIUM RESPONSE AND TREATMENT RESISTANCE IN MAJOR DEPRESSIVE DISORDER
Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Jonsson L; Clements C; Andersson E; Boberg J; Lewis C; Sullivan P; Landén M; Lu Y
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2022;63:e198
T55. POLYGENICITY OF COMORBID DEPRESSION IN MULTIPLE SCLEROSIS
Kowalec K; Salter A; Fitzgerald KC; Harder A; Lu Y; Dolovich C; Hägg S; Hitchon C; Bernstein CN; Cutter G; Bolton JM; McKay K; Graff LA; Patten S; Marrie RA
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2022;63:e32-e33
NEXT GENERATION GENOME-WIDE ASSOCIATION STUDY OF SCHIZOPHRENIA FROM SWEDEN
Kowalec K; Karlsson R; Lu Y; Song J; Yao S; Szatkiewicz J; Kähler A; Schalling M; Österholm A-M; Hultman C; Lavebratt C; Landen M; Karlsson H; Dalman C; Sullivan P
Article: GENERAL HOSPITAL PSYCHIATRY. 2022;77:21-28
Depressive symptom trajectories and polygenic risk scores in individuals with an immune-mediated inflammatory disease
Kowalec K; Salter A; Fitzgerald KC; Patel M; Han J; Lu Y; Bolton JM; Hitchon C; Bernstein CN; Patten S; Graff LA; Marriott JJ; Marrie RA
Article: BMC RESEARCH NOTES. 2022;15(1):162
Trends of COVID-19 incidence in Manitoba and public health measures: March 2020 to February 2022
Aboulatta L; Kowalec K; Delaney J; Alessi-Severini S; Leong C; Falk J; Eltonsy S
Article: MOLECULAR PSYCHIATRY. 2022;27(5):2439-2447
The impact of educational attainment, intelligence and intellectual disability on schizophrenia: a Swedish population-based register and genetic study
Song J; Yao S; Kowalec K; Lu Y; Sariaslan A; Szatkiewicz JP; Larsson H; Lichtenstein P; Hultman CM; Sullivan PF
Article: MOLECULAR PSYCHIATRY. 2022;27(3):1667-1675
Genetic heterogeneity and subtypes of major depression
Thuy-Dung N; Harder A; Xiong Y; Kowalec K; Hagg S; Cai N; Kuja-Halkola R; Dalman C; Sullivan PF; Lu Y
Article: JAMA PSYCHIATRY. 2022;79(3):260-269
Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia
Pardinas AF; Smart SE; Willcocks IR; Holmans PA; Dennison CA; Lynham AJ; Legge SE; Baune BT; Bigdeli TB; Cairns MJ; Corvin A; Fanous AH; Frank J; Kelly B; McQuillin A; Melle I; Mortensen PB; Mowry BJ; Pato CN; Periyasamy S; Rietschel M; Rujescu D; Simonsen C; St Clair D; Tooney P; Wu JQ; Andreassen OA; Kowalec K; Sullivan PF; Murray RM; Owen MJ; MacCabe JH; O'Donovan MC; Walters JTR
Article: FRONTIERS IN PHARMACOLOGY. 2022;13:886652
Psychotropic Medication Use Before and During COVID-19: A Population-Wide Study
Leong C; Kowalec K; Eltonsy S; Bolton JM; Enns MW; Tan Q; Yogendran M; Chateau D; Delaney JA; Sareen J; Falk J; Spiwak R; Logsetty S; Alessi-Severini S
Article: PLOS ONE. 2022;17(11):e0278072
Drug utilization patterns before and during COVID-19 pandemic in Manitoba, Canada: A population-based study
Aboulatta L; Peymani P; Vaccaro C; Leong C; Kowalec K; Delaney J; Falk J; Alessi-Severini S; Aloud B; Eltonsy S
Article: FRONTIERS IN PHARMACOLOGY. 2022;13:871136
Trends of Utilization of Antiseizure Medications Among Pregnant Women in Manitoba, Canada: A 20-Year Population-Based Study
Shouman W; Delaney JA; Kowalec K; Ng M; Ruth C; Falk J; Leong C; Alessi-Severini S; Lavu A; Peymani P; Eltonsy S
Article: ACR OPEN RHEUMATOLOGY. 2021;3(12):889-896
Prevalence and Risk Factors of Substance Use Disorder in Rheumatoid Arthritis
Kowalec K; Carney H; Patel M; Hitchon C; Bolton JM; Patten SB; Graff LA; Bernstein CN; Peschken C; Marrie RA
Article: MULTIPLE SCLEROSIS JOURNAL. 2021;27(13):2077-2084
Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis
Harroud A; Marrie RA; Fitzgerald KC; Salter A; Lu Y; Patel M; Kowalec K
Article: MOLECULAR PSYCHIATRY. 2021;26(8):4487-4495
Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study
Kowalec K; Lu Y; Sariaslan A; Song J; Ploner A; Dalman C; Hultman CM; Larsson H; Lichtenstein P; Sullivan PF
Article: TRANSLATIONAL PSYCHIATRY. 2021;11(1):163
The association between family history and genomic burden with schizophrenia mortality: a Swedish population-based register and genetic sample study
Kowalec K; Lu Y; Song J; Dalman C; Hultman CM; Larsson H; Lichtenstein P; Sullivan PF
Article: ELIFE. 2021;10:e58430
DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia
Hannon E; Dempster EL; Mansell G; Burrage J; Bass N; Bohlken MM; Corvin A; Curtis CJ; Dempster D; Di Forti M; Dinan TG; Donohoe G; Gaughran F; Gill M; Gillespie A; Gunasinghe C; Hulshoff HE; Hultman CM; Johansson V; Kahn RS; Kaprio J; Kenis G; Kowalec K; MacCabe J; McDonald C; McQuillin A; Morris DW; Murphy KC; Mustard CJ; Nenadic I; O'Donovan MC; Quattrone D; Richards AL; Rutten BP; St Clair D; Therman S; Toulopoulou T; Van Os J; Waddington JL; Sullivan P; Vassos E; Breen G; Collier DA; Murray RM; Schalkwyk LS; Mill J
Article: INFLAMMATORY BOWEL DISEASES. 2021;27(1):58-64
Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease
Carney H; Marrie RA; Bolton JM; Patten SB; Graff LA; Bernstein CN; Kowalec K
Article: NEUROLOGY. 2020;95(5):e446-e456
Comorbidity is associated with disease activity in MS Findings from the CombiRx trial
Salter A; Kowalec K; Fitzgerald KC; Cutter G; Marrie RA
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29:s236
T36UNDERSTANDING PSYCHIATRIC COMORBIDITY IN CHRONIC IMMUNOINFLAMMATORY DISEASES USING GENOMICS
Kowalec K; Bernstein CN; Hitchon C; Bolton J; Marrie RA
Article: TRANSLATIONAL PSYCHIATRY. 2019;9(1):157
Methylation age acceleration does not predict mortality in schizophrenia
Kowalec K; Hannon H; Mansell G; Burrage J; Ori APS; Ophoff RA; Mill J; Sullivan PF
Article: NATURE GENETICS. 2018;50(8):1081-1085
Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis
Kowalec K; Wright GEB; Drogemoller BI; Aminkeng F; Bhavsar AP; Kingwell E; Yoshida EM; Traboulsee A; Marrie RA; Kremenchutzky M; Campbell TL; Duquette P; Chalasani N; Wadelius M; Hallberg P; Xia Z; De Jager PL; Denny JC; Davis MF; Ross CJD; Tremlett H; Carleton BC
Article: NEUROLOGY. 2018;90(4):e332-e341
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients
McCormack M; Gui H; Ingason A; Speed D; Wright GEB; Zhang EJ; Secolin R; Yasuda C; Kwok M; Wolking S; Becker F; Rau S; Avbersek A; Heggeli K; Leu C; Depondt C; Sills GJ; Marson AG; Auce P; Brodie MJ; Francis B; Johnson MR; Koeleman BPC; Striano P; Coppola A; Zara F; Kunz WS; Sander JW; Lerche H; Klein KM; Weckhuysen S; Krenn M; Gudmundsson LJ; Stefansson K; Krause R; Shear N; Ross CJD; Delanty N; Pirmohamed M; Carleton BC; Cendes F; Lopes-Cendes I; Liao W-P; O'Brien TJ; Sisodiya SM; Cherny S; Kwan P; Baum L; Cavalleri GL
Article: NEUROLOGY. 2017;89(24):2455-2461
Comorbidity increases the risk of relapse in multiple sclerosis A prospective study
Kowalec K; McKay KA; Patten SB; Fisk JD; Evans C; Tremlett H; Marrie RA
Journal article: JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS. 2017;88:173
Genome-wide Scan Identifies Association Between an Interferon Regulatory Factor Variant and Interferon-beta Induced Liver Injury in Multiple Sclerosis Patients
Kowalec K; Wright GEB; Drögemöller BI; Aminkeng F; Bhavsar AP; Kingwell E; Yoshida EM; Traboulsee A; Marrie RA; Kremenchutzky M; Campbell TL; Duquette P; Chalasani N; Wadelius M; Hallberg P; Xia Z; De Jager P; Ross C; Tremlett H; Carleton B
Journal article: JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS. 2017;88:167
Pharmacogenomic Prediction of Ribavirin-Induced Hemolytic Anemia in Patients Treated for Hepatitis C Infection
Abel S; Aminkeng F; Kowalec K; Drogemoller B; Wright G; Bader R; Stortz J; Yoshida E; Lee S; Al-Judaibi B; Kim R; Tam E; Ramji A; Ross C; Carleton B
Article: BMJ OPEN. 2017;7(5):e016276
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia
Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Tremlett H
Article: DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2016;85(3):328-333
Discordant diagnostic results due to a hepatitis B virus T123A HBsAg mutant
Osiowy C; Kowalec K; Giles E
Article: NATURE GENETICS. 2015;47(9):1079-1084
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
Aminkeng F; Bhavsar AP; Visscher H; Rassekh SR; Li Y; Lee JW; Brunham LR; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Amstutz U; Rieder MJ; Bernstein D; Carleton BC; Hayden MR; Ross CJD
Article: JOURNAL OF VIRAL HEPATITIS. 2013;20(2):122-130
Genetic diversity of hepatitis B virus genotypes B6, D and F among circumpolar indigenous individuals
Kowalec K; Minuk GY; Borresen ML; Koch A; McMahon BJ; Simons B; Osiowy C
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2013;2(1):57-59
Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient
Kowalec K; Yoshida EM; Traboulsee A; Carleton B; Tremlett H
Article: JOURNAL OF MEDICAL VIROLOGY. 2012;84(9):1369-1375
The prevalence and long term outcome of occult hepatitis B virus infections in community based populations
Minuk GY; Kowalec K; Caouette S; Larke B; Osiowy C
Article: JOURNAL OF MEDICAL VIROLOGY. 2010;82(6):942-948
Molecular Characterization of Hepatitis B Virus and a 9-Year Clinical Profile in a Patient Infected With Genotype I
Osiowy C; Kaita K; Solar K; Mendoza K
Visa fler

Alla övriga publikationer

Preprint: MEDRXIV. 2023
Subtyping Schizophrenia Using Psychiatric Polygenic Scores
Lu Y; Kowalec K; Song J; Karlsson R; Harder A; Giusti-Rodríguez P; Sullivan PF; Yao S
Preprint: RES SQ. 2023;RES SQ
Investigating genetic overlap between antidepressant and lithium response and treatment resistance in major depressive disorder.
Lu Y; Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigstrom R; Jonsson L; Clements C; Andersson E; Boberg J; Lewis C; Sullivan P; Landén M
Review: FRONTIERS IN IMMUNOLOGY. 2023;14:1197195
Etiology, effects and management of comorbidities in multiple sclerosis: recent advances
Marrie RA; Fisk JD; Fitzgerald K; Kowalec K; Maxwell C; Rotstein D; Salter A; Tremlett H
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2022;63:E159
POLYGENIC RISK AND BODY MASS INDEX IN THE SWE-DEN SCHIZOPHRENIA STUDY
Kowalec K; Song J; Yao S; Karlsson R; Lu Y; Bergen S; Harder A; Kahler A; Osterholm A-M; Hultman C; Sullivan P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2022;63:E50
GENETIC EPIDEMIOLOGY AND POLYGENICITY OF PSYCHOTIC MAJOR DEPRESSIVE DISORDER
Thi TDN; Kuja-Halkola R; Kowalec K; Harder A; Xiong Y; Landen M; Hagg S; Lichtenstein P; Larsson H; Buil A; Meijsen J; Sullivan P; Dalman C; Pasman J; Lu Y
Preprint: MEDRXIV. 2022
COVID-19 pandemic impact on preterm birth and stillbirth rates associated with socioeconomic disparities: A quasi-experimental study
Aboulatta L; Kowalec K; Leong C; Delaney J; Falk J; Alessi-Severini S; Chateau D; Tan Q; Kearns K; Raimondi C; Lavu A; Haidar L; Vaccaro C; Eltonsy S
Review: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2022;111(4):919-930
A Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics
Johnson D; Wilke MAP; Lyle SM; Kowalec K; Jorgensen A; Wright GEB; Drogemoller BI
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(1_SUPPL):52
Biostatistical Methods
Hu C; Marrie RA; Salter A; Kowalec K; Fitzgerald K
Conference publication: BIRTH DEFECTS RESEARCH. 2022;114(9):395
Impact of COVID-19 Pandemic on Preterm Birth and Stillbirth Rates in Manitoba, Canada: A Quasi-Experimental Study
Aboulatta L; Kowalec K; Leong C; Delaney J; Falk J; Alessi-Severini S; Eltonsy S
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):212
Polygenicity of comorbid depression in multiple sclerosis
Kowalec K; Salter A; Fitzgerald KC; Harder A; Lu Y; Dolovich C; Hagg S; Hitchon C; Bernstein CN; Cutter G; Marriott JJ; Bolton JM; McKay K; Graff LA; Patten S; Marrie RA
Review: PSYCHOLOGICAL MEDICINE. 2021;51(13):2168-2177
Genetic architecture of schizophrenia: a review of major advancements
Legge SE; Santoro ML; Periyasamy S; Okewole A; Arsalan A; Kowalec K
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021;51:E137-E138
THE IMPACT OF EDUCATIONAL ATTAINMENT, IN-TELLIGENCE AND INTELLECTUAL DISABILITY ON SCHIZOPHRENIA: A SWEDISH POPULATION-BASED REGISTER AND GENETIC STUDY
Song J; Yao S; Kowalec K; Lu Y; Sariaslan A; Szatkiewicz J; Larsson H; Lichtenstein P; Hultman C; Sullivan P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021;51:E237
CLUSTERING OF SCHIZOPHRENIA CASES BASED ON COMMON GENETIC VARIANTS
Yao S; Lu Y; Kowalec K; Song J; Karlsson R; Harder A; Sullivan P
Preprint: MEDRXIV. 2021
Genetic heterogeneity and subtypes of major depression
Nguyen T-D; Harder A; Xiong Y; Kowalec K; Hägg S; Cai N; Kuja-Halkola R; Dalman C; Sullivan P; Lu Y
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(1_SUPPL):58-59
Mendelian Randomization Provides No Evidence for a Causal Role in the Bidirectional Relationship Between Depression and Multiple Sclerosis
Harroud A; Marrie R; Richards B; Fitzgerald K; Salter A; Lu Y; Patel M; Kowalec K
Preprint: BIORXIV. 2020
Large-scale analysis of DNA methylation identifies cellular alterations in blood from psychosis patients and molecular biomarkers of treatment-resistant schizophrenia
Hannon E; Dempster EL; Mansell G; Burrage J; Bass N; Bohlken MM; Corvin A; Curtis CJ; Dempster D; Di Forta M; Dinan TG; Donohoe G; Gaughran F; Gill M; Gillespie A; Gunasinghe C; Hulshoff HE; Hultman CM; Johansson V; Kahn RS; Kaprio J; Kenis G; Kowalec K; MacCabe J; McDonald C; McQuillin A; Morris DW; Murphy KC; Mustard C; Nenadic I; O’Donovan MC; Quattrone D; Richards AL; Rutten BP; St Clair D; Therman S; Toulopoulou T; Van Os J; Waddington JL; Consortium WTCC; consortium CA; Sullivan P; Vassos E; Breen G; Collier DA; Murray R; Schalkwyk LS; Mill J
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29:S184
TRYGGVE2: PREDICTING POOR OUTCOMES IN MAJOR DEPRESSION USING REGISTER GENOMICS IN SWEDEN
Lu Y; Kowalec K; Drange OK; Tesli M; Weinsheimer S; Folkersen L; Werge T; Andreassen O; Reichborn-Kjennerud T; Sullivan P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29:S85-S86
TRYGGVE2: PREDICTING POOR OUTCOMES IN SCHIZOPHRENIA USING REGISTER GENOMICS IN SWEDEN
Kowalec K; Yi L; Drange OK; Weinsheimer S; Tesli M; Folkersen L; Werge T; Andreassen OA; Reichborn-Kjennerud T; Sullivan P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29:S215
INCREASED SCHIZOPHRENIA FAMILY HISTORY BURDEN AND REDUCED PREMORBID IQ IN TREATMENT-RESISTANT SCHIZOPHRENIA: A SWEDISH NATIONAL REGISTER AND GENOMIC STUDY
Kowalec K; Yi L; Sariaslan A; Song J; Ploner A; Dalman C; Hultman C; Larsson H; Lichtenstein P; Sullivan P
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:648
Understanding psychiatric comorbidity in multiple sclerosis using genomics
Kowalec K; Bernstein CN; Hitchon C; Bolton J; Marrie RA
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29:1099-1100
METHYLOMIC BIOMARKERS OF SCHIZOPHRENIA AND ANTIPSYCHOTIC MEDICATION EXPOSURE
Hannon E; Dempster E; Mansell G; Schalkwyk L; Murray R; McQuillin A; Kowalec K; St Clair D; Morris D; Sullivan P; O'Donovan M; MacCabe J; Collier D; Mill J
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29:1332-1333
PREDICTION OF MORTALITY USING DNA METHYLATION AGE IN SCHIZOPHRENIA
Kowalec K; Hannon E; Mansell G; Burrage J; Mill J; Sullivan P
Editorial comment: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2017;12:1-3
From bugs to brains: The microbiome in neurological health
Mckay KA; Kowalec K; Brinkman F; Finlay BB; Horwitz M; Manges AR; Osborne L; Tremlett H
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:991
Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study
Kowalec K; McKay K; Patten SB; Fisk JD; Evans C; Tremlett H; Marrie RA
Review: EXPERT OPINION ON DRUG SAFETY. 2014;13(10):1305-1317
Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients
Kowalec K; Kingwell E; Yoshida EM; Marrie RA; Kremenchutzky M; Campbell TL; Wadelius M; Carleton B; Tremlett H
Review: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2013;2(3):183-192
The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis
Kowalec K; Carleton B; Tremlett H
Visa fler

Forskningsbidrag

Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
Canadian Institutes of Health Research
1 January 2023 - 31 December 2023
Precision Genomics Suite
Canada Foundation for Innovation
22 November 2022
Psychiatric Disorder Genomic Risk Scores as a Correlate of Disease Activity and Progression in Multiple Sclerosis
Congressionally Directed Medical Research Programs
15 July 2020 - 14 July 2024
Enhancing CAN-AIM capacity to respond to drug safety and effectiveness queries
Canadian Institutes of Health Research
1 September 2019 - 31 August 2022
Identifying Clinical, Demographic, & Genomic Risk Factors for Treatment-Resistant Psychiatric Disorders
Canadian Institutes of Health Research
1 April 2018 - 3 January 2019
The Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Program
Canadian Institutes of Health Research
1 November 2015 - 28 February 2022
Genotype specific approaches to beta-interferon therapy in Multiple Sclerosis
Canadian Institutes of Health Research
1 May 2011 - 31 October 2014

Anställningar

Assistant Professor, Genetics, University of Manitoba, 2019-
Anknuten till Forskning, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2022-2025

Examina och utbildning

PhD, Genetics and epidemiology, University of British Columbia, 2016
MSc, Viral genetics, University of Manitoba, 2011
BSc, Microbiology, University of Manitoba, 2008

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI